Atara Biotherapeutics
ATRA
43 hedge funds and large institutions have $31.5M invested in Atara Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
61% more capital invested
Capital invested by funds: $19.6M → $31.5M (+$11.9M)
23% more funds holding
Funds holding: 35 → 43 (+8)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
1.47% less ownership
Funds ownership: 42.58% → 41.12% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$666K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$263K |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
+$232K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$134K |
| 5 |
Morgan Stanley
New York
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.75M |
| 2 |
CC
Centiva Capital
New York
|
-$353K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$111K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$49.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.4K |
ATRA Hedge Fund Activity: Q4 2024 in Review
43 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2024, worth a combined $31.5M — up 61% from $19.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATRA positions and 3 closed out — a net gain of 8 holders — while 13 added to existing stakes and 11 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $666K. The largest seller was Millennium Management, cutting an estimated $1.75M.
- 43 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2024, up from 35 in Q3 2024.
- Funds reported $31.5M of Atara Biotherapeutics stock for Q4 2024, up 61% quarter-over-quarter.
- 11 funds opened new Atara Biotherapeutics positions in Q4 2024 and 3 closed out, a net change of +8 holders.
- The largest Atara Biotherapeutics buyer in Q4 2024 was EcoR1 Capital, an estimated $666K added.
- The largest Atara Biotherapeutics seller in Q4 2024 was Millennium Management, an estimated $1.75M sold.
Based on aggregated 13F filings for Q4 2024.